"The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS), which releases the drug everolimus to limit the growth of scar ti"...
(Generic versions may still be available.)
Endrate (Edetate Disodium Injection, USP) is indicated in selected patients for the emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity.
DOSAGE AND ADMINISTRATION
Edetate Disodium Injection, USP is administered by intravenous infusion only after dilution.
For Adults: The recommended daily dosage is 50 mg/kg of body weight to a maximum dose of 3 g in 24 hours. The dose, calculated by body weight, should be diluted in 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP. The intravenous infusion should be regulated so that three or more hours are required for completion and the cardiac reserve of the patient is not exceeded. A suggested regimen includes five consecutive daily doses followed by two days without medication, with repeated courses as necessary to a total of 15 doses.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
Endrate (Edetate Disodium Injection, USP) is supplied in 20 mL (3 g) ampuls, List No. 6940.
Store at 25°C (77°F) with excursions permitted between 15° to 30°C (59° to 86°F).
Rev: May, 2004. Hospira, Inc., Lake Forest, IL 60045 USA.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/5/2017
Additional Endrate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.